These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 25567553)

  • 1. Dementia praecox redux: a systematic review of the nicotinic receptor as a target for cognitive symptoms of schizophrenia.
    Rowe AR; Mercer L; Casetti V; Sendt KV; Giaroli G; Shergill SS; Tracy DK
    J Psychopharmacol; 2015 Feb; 29(2):197-211. PubMed ID: 25567553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the α7 nicotinic receptor in cognitive processing of persons with schizophrenia.
    AhnAllen CG
    Curr Opin Psychiatry; 2012 Mar; 25(2):103-8. PubMed ID: 22262029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
    Martin LF; Freedman R
    Int Rev Neurobiol; 2007; 78():225-46. PubMed ID: 17349863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-Furan-2-yl-N-p-tolyl-acrylamide, a positive allosteric modulator of the α7 nicotinic receptor, reverses schizophrenia-like cognitive and social deficits in rats.
    Potasiewicz A; Hołuj M; Kos T; Popik P; Arias HR; Nikiforuk A
    Neuropharmacology; 2017 Feb; 113(Pt A):188-197. PubMed ID: 27717880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. α7 Nicotinic Acetylcholine Receptor: A Potential Target in Treating Cognitive Decline in Schizophrenia.
    Jones C
    J Clin Psychopharmacol; 2018 Jun; 38(3):247-249. PubMed ID: 29505470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stimulation of nicotinic acetylcholine alpha7 receptors rescue schizophrenia-like cognitive impairments in rats.
    Potasiewicz A; Nikiforuk A; Hołuj M; Popik P
    J Psychopharmacol; 2017 Feb; 31(2):260-271. PubMed ID: 28168926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia.
    Ishikawa M; Hashimoto K
    Curr Pharm Des; 2011; 17(2):121-9. PubMed ID: 21355839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Going up in smoke? A review of nAChRs-based treatment strategies for improving cognition in schizophrenia.
    Boggs DL; Carlson J; Cortes-Briones J; Krystal JH; D'Souza DC
    Curr Pharm Des; 2014; 20(31):5077-92. PubMed ID: 24345265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Procognitive effects of varenicline in the animal model of schizophrenia depend on α4β2- and α 7-nicotinic acetylcholine receptors.
    Potasiewicz A; Golebiowska J; Popik P; Nikiforuk A
    J Psychopharmacol; 2018 Dec; 33(1):269881118812097. PubMed ID: 30501536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the discovery of novel positive allosteric modulators of the alpha7 nicotinic acetylcholine receptor.
    Faghih R; Gfesser GA; Gopalakrishnan M
    Recent Pat CNS Drug Discov; 2007 Jun; 2(2):99-106. PubMed ID: 18221220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.
    Hauser TA; Kucinski A; Jordan KG; Gatto GJ; Wersinger SR; Hesse RA; Stachowiak EK; Stachowiak MK; Papke RL; Lippiello PM; Bencherif M
    Biochem Pharmacol; 2009 Oct; 78(7):803-12. PubMed ID: 19482012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α7 nicotinic acetylcholine receptors as therapeutic targets in schizophrenia: Update on animal and clinical studies and strategies for the future.
    Terry AV; Callahan PM
    Neuropharmacology; 2020 Jun; 170():108053. PubMed ID: 32188568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study.
    Winterer G; Gallinat J; Brinkmeyer J; Musso F; Kornhuber J; Thuerauf N; Rujescu D; Favis R; Sun Y; Franc MA; Ouwerkerk-Mahadevan S; Janssens L; Timmers M; Streffer JR
    Neuropharmacology; 2013 Jan; 64():197-204. PubMed ID: 22766391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuronal nicotinic acetylcholine receptors - targets for the development of drugs to treat cognitive impairment associated with schizophrenia and Alzheimer's disease.
    Haydar SN; Dunlop J
    Curr Top Med Chem; 2010; 10(2):144-52. PubMed ID: 20166959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology.
    Thomsen MS; Hansen HH; Timmerman DB; Mikkelsen JD
    Curr Pharm Des; 2010 Jan; 16(3):323-43. PubMed ID: 20109142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.
    Ochoa EL; Lasalde-Dominicci J
    Cell Mol Neurobiol; 2007 Aug; 27(5):609-39. PubMed ID: 17554626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating the cognitive deficits of schizophrenia with alpha4beta2 neuronal nicotinic receptor agonists.
    Radek RJ; Kohlhaas KL; Rueter LE; Mohler EG
    Curr Pharm Des; 2010 Jan; 16(3):309-22. PubMed ID: 20109141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nicotinic interactions with antipsychotic drugs, models of schizophrenia and impacts on cognitive function.
    Levin ED; Rezvani AH
    Biochem Pharmacol; 2007 Oct; 74(8):1182-91. PubMed ID: 17714691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cog in cognition: how the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits.
    Leiser SC; Bowlby MR; Comery TA; Dunlop J
    Pharmacol Ther; 2009 Jun; 122(3):302-11. PubMed ID: 19351547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats.
    Nikiforuk A; Kos T; Hołuj M; Potasiewicz A; Popik P
    Neuropharmacology; 2016 Feb; 101():389-400. PubMed ID: 26232639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.